Zacks Research Issues Positive Estimate for Zoetis Earnings

Zoetis Inc. (NYSE:ZTS) – Zacks Research boosted their Q1 2026 earnings per share (EPS) estimates for Zoetis in a research note issued on Tuesday, December 3rd. Zacks Research analyst E. Bagri now forecasts that the company will post earnings of $1.63 per share for the quarter, up from their prior estimate of $1.62. The consensus estimate for Zoetis’ current full-year earnings is $5.90 per share. Zacks Research also issued estimates for Zoetis’ Q2 2026 earnings at $1.77 EPS and FY2026 earnings at $6.94 EPS.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Monday, November 4th. The company reported $1.58 EPS for the quarter, topping analysts’ consensus estimates of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The business had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.29 billion. During the same period in the previous year, the company posted $1.36 earnings per share. The business’s revenue for the quarter was up 11.6% on a year-over-year basis.

A number of other brokerages also recently issued reports on ZTS. Argus raised Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Leerink Partners began coverage on Zoetis in a report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price target for the company. BTIG Research upped their price target on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a report on Monday, August 12th. Piper Sandler increased their price objective on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a report on Wednesday, August 14th. Finally, Leerink Partnrs raised Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. Eleven investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $220.80.

Zoetis Stock Performance

Shares of ZTS opened at $176.46 on Friday. The stock has a 50 day moving average price of $182.43 and a 200 day moving average price of $180.93. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26. The company has a market capitalization of $79.61 billion, a price-to-earnings ratio of 33.17, a price-to-earnings-growth ratio of 2.86 and a beta of 0.89. Zoetis has a 52-week low of $144.80 and a 52-week high of $201.92.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, December 3rd. Stockholders of record on Thursday, October 31st were paid a dividend of $0.432 per share. This represents a $1.73 annualized dividend and a dividend yield of 0.98%. The ex-dividend date of this dividend was Thursday, October 31st. Zoetis’s dividend payout ratio (DPR) is presently 32.52%.

Institutional Investors Weigh In On Zoetis

Large investors have recently modified their holdings of the stock. Simplify Asset Management Inc. purchased a new position in Zoetis in the third quarter worth $11,684,000. Bank Pictet & Cie Asia Ltd. raised its position in Zoetis by 41.0% in the second quarter. Bank Pictet & Cie Asia Ltd. now owns 37,500 shares of the company’s stock worth $6,501,000 after acquiring an additional 10,900 shares in the last quarter. B&L Asset Management LLC purchased a new position in Zoetis in the third quarter worth $563,000. Swedbank AB raised its position in Zoetis by 56.2% in the second quarter. Swedbank AB now owns 1,946,277 shares of the company’s stock worth $337,407,000 after acquiring an additional 700,398 shares in the last quarter. Finally, Dai ichi Life Insurance Company Ltd raised its position in Zoetis by 16.3% in the third quarter. Dai ichi Life Insurance Company Ltd now owns 74,499 shares of the company’s stock worth $14,556,000 after acquiring an additional 10,427 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.